Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neuroendocrine Tumors 4Sarcoma 2Neoplasms 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Lymphoma 1Cholangiocarcinoma 1Carcinoid Tumor 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1

Interventions

durvalumab 7Carboplatin 7Docetaxel 6Paclitaxel 5Nivolumab 5talazoparib 4linifanib 4Cisplatin 4trifluridine tipiracil drug combination 3tremelimumab 3tislelizumab 3depatuxizumab 3ST 1481 3S 1 (combination) 3Panobinostat 3Gemcitabine 3zimberelimab 2toripalimab 2olaparib 2motesanib diphosphate 2mogamulizumab 2TAS-114 2Sorafenib 2Rifampin 2PM 01183 2Oxaliplatin 2MLN 8237 2Itraconazole 2Injections 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumors × surufatinib × Clear all
NCT04169672 2023-03-02

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Hutchmed

Phase 2 Completed
248 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡